Full Text
Cost-Utility of Idelalisib In Combination with Rituximab In Relapsed or Refractory Chronic Lymphocytic Leukemia

Abstract

Authors

LF Casado JA Hernandez I Jarque M Echave MÁ Casado A Castro-Gomez

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×